Home>Topics>Stocks>Orexigen Therapeutics

Orexigen Therapeutics OREX

  1. All
  2. Commentary
  3. Headlines
    1. UPDATE 2-FDA delays decision on Orexigen's obesity drug by 3 months

      Headlines

      Wed, 11 Jun 2014

      June 11 (Reuters) - Orexigen Therapeutics Inc said the U.S. Food and Drug Administration delayed a decision on the marketing application for its obesity drug, contrave, by three months, sending the...

    2. FDA delays decision on Orexigen's obesity drug by three months

      Headlines

      Wed, 11 Jun 2014

      June 11 (Reuters) - Orexigen Therapeutics Inc said the U.S. Food and Drug Administration delayed its decision on the marketing application of its obesity drug, contrave, by three months, sending its...

    3. Diet drug makers Vivus, Orexigen fall ahead of FDA decision

      Headlines

      Tue, 17 Jul 2012

      (Reuters) - Shares of weight-loss drug makers Vivus Inc and Orexigen Therapeutics Inc fell ahead of an anticipated deadline by the end of Tuesday for the U.S. Food and Drug Administration to decide...

    4. Vivus, Orexigen diet pills show positive heart-safety

      Headlines

      Mon, 4 Apr 2011

      BANGALORE (Reuters) - After a spate of disappointments, weight-loss drugmakers Vivus Inc and Orexigen Therapeutics Inc said clinical data suggested reduced heart risks associated with diet pills,...

    5. Arena Rival Orexigen Needs Heart Safety Trial, Highlights Risks of Obesity Drug Development

      Commentary

      Tue, 1 Feb 2011

      Orexigen Therapeutics ' OREX stock took a nose dive Tuesday when the firm announced it received a complete response letter from the Food and Drug Administration

    6. EnteroMedics' Shares Rise on Optimism about Orexigen's Diet Drug

      Commentary

      Wed, 8 Dec 2010

      its shares run up substantially following a Food and Drug Administration panel decision to recommend approval of Orexigen's OREX weight loss drug candidate Contrave. The panel's recommendation was somewhat surprising, especially since it had not supported

    7. Orexigen's Obesity Drug Receives Surprise Panel Recommendation; We Remain Negative on Arena

      Commentary

      Wed, 8 Dec 2010

      In a surprise move Tuesday, a Food and Drug Administration advisory panel voted to recommend approval of Orexigen Therapeutics ' OREX diet drug Contrave. This comes after advisory panels voted against recommending diet drugs from Arena Pharmaceuticals

    8. Panel Ahead for Arena's drug

      Commentary

      Wed, 30 Jun 2010

      for lorcaserin on September 16, about one month before the FDA action date on October 22. Another close competitor, Orexigen OREX , has a panel meeting for its drug Contrave set for December, well after Arena's action date. However, the Contrave decision

    9. Dropping Coverage of Orexigen

      Commentary

      Mon, 3 Aug 2009

      We are no longer providing equity research on Orexigen Therapeutics OREX . We provide broad coverage of more than 1,800 companies across 91 industry groups and adjust our coverage as necessary based on client demand and investor interest.

    10. Orexigen's Pivotal Trials Meet Endpoint

      Commentary

      Mon, 20 Jul 2009

      Orexigen Therapeutics OREX announced Monday that its much-anticipated Phase III program evaluating antiobesity drug Contrave met its primary endpoint

    « Prev12Next »
    Content Partners